The expansion of manufacturing capabilities will increase production capacity for biological substrates and advanced pharmaceutical formulations, while improving supply chain efficiency and supporting global market development.
All manufacturing processes are designed to meet international quality standards and Good Manufacturing Practice (cGMP) requirements, ensuring consistent quality control and production reliability.
The expansion represents another step in Fazax's development of a global manufacturing network and strengthens the company's ability to deliver innovative biotechnology solutions to international markets.